Clinical dilemmas in ovarian tissue cryopreservation.
| Autor: | Dunlop CE; Obstetrics & Gynaecology Department, Edinburgh Royal Infirmary, Edinburgh, United Kingdom. Electronic address: cheryl.dunlop@nhs.scot., Anderson RA; Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, United Kingdom. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Fertility and sterility [Fertil Steril] 2024 Oct; Vol. 122 (4), pp. 559-564. Date of Electronic Publication: 2024 May 31. |
| DOI: | 10.1016/j.fertnstert.2024.05.167 |
| Abstrakt: | Ovarian tissue cryopreservation (OTC) is increasingly offered globally as a fertility preservation strategy for both postpubertal women and prepubertal girls, with subsequent reimplantation of cryopreserved ovarian cortex resulting in a rapidly growing number of live births. There remains very limited evidence of efficacy from tissue stored when the patient was prepubertal or from conditions affecting the ovary directly, e.g., Turner syndrome. Although OTC is becoming a more established practice, several clinical dilemmas remain from a practical and ethical standpoint. This review discusses the challenges regarding optimal patient selection for the procedure, the use of OTC in patients with a poor prognosis, the potential of reimplantation of tissue contaminated with malignant cells, and the role of OTC in those with an intrinsic ovarian disorder. Competing Interests: Declaration of Interests C.E.D. has nothing to disclose. R.A.A. has received consulting fees from Roche Diagnostics outside the submitted work. (Crown Copyright © 2024. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|